STAT3 and hepatocellular carcinoma: Similar inhibition of STAT3 signaling in some cancers, including HCC was reported when treating with sorafenib53,62, bevacizumab71,72, ramucirumab26,67, panitumumab71,73,74, and a combination of sorafenib with an anti-EGFRvIII53.